Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Net Income (2016 - 2025)

Historic Net Income for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$67.0 million.

  • Celldex Therapeutics' Net Income fell 5917.0% to -$67.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.5 million, marking a year-over-year decrease of 4572.71%. This contributed to the annual value of -$157.9 million for FY2024, which is 1162.0% down from last year.
  • Per Celldex Therapeutics' latest filing, its Net Income stood at -$67.0 million for Q3 2025, which was down 5917.0% from -$56.6 million recorded in Q2 2025.
  • Celldex Therapeutics' Net Income's 5-year high stood at -$13.4 million during Q2 2021, with a 5-year trough of -$67.0 million in Q3 2025.
  • For the 5-year period, Celldex Therapeutics' Net Income averaged around -$34.7 million, with its median value being -$32.8 million (2024).
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 16922.9% in 2022, then soared by 1528.16% in 2023.
  • Quarter analysis of 5 years shows Celldex Therapeutics' Net Income stood at -$20.1 million in 2021, then crashed by 31.46% to -$26.5 million in 2022, then tumbled by 63.5% to -$43.3 million in 2023, then fell by 8.74% to -$47.1 million in 2024, then crashed by 42.37% to -$67.0 million in 2025.
  • Its last three reported values are -$67.0 million in Q3 2025, -$56.6 million for Q2 2025, and -$53.8 million during Q1 2025.